Goldman Sachs’s BiomX Inc. Units each consisting of one share of common stock and one Warrant entitling the holder to purchase one-half of a share of common stock PHGE.U Stock Holding History

Goldman Sachs’s Portfolio PHGE.U Stock Details PHGE.U Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,039	Closed	-$2.91K	–	6142
2024 Q2	$2.91K	Hold	1,039	–	–	﹤0.01%	5585
2024 Q1	$2.55K	Sell	1,039 -10	-1%	-$33	﹤0.01%	5483
2023 Q4	$1.37K	Hold	1,049	–	–	﹤0.01%	5566
2023 Q3	$2.64K	Hold	1,049	–	–	﹤0.01%	5468
2023 Q2	$2.63K	Hold	1,049	–	–	﹤0.01%	5675
2023 Q1	$2.52K	Hold	1,049	–	–	﹤0.01%	5843
2022 Q4	$2.31K	Hold	1,049	–	–	﹤0.01%	5870
2022 Q3	$7K	Buy	+1,049	New	+$9.44K	﹤0.01%	6062

Other funds holding PHGE.U

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs's PHGE.U Position: Q3 2024 in Review

Goldman Sachs sold out of BiomX Inc. Units each consisting of one share of common stock and one Warrant entitling the holder to purchase one-half of a share of common stock (PHGE.U) in Q3 2024, closing a stake of 1,039 shares — an estimated $2.91K sold.

Goldman Sachs first reported a position in PHGE.U in Q3 2022 and held it in 8 quarters. The position peaked at $7K in Q3 2022. 2 funds tracked by Wall St. Rank hold PHGE.U as of Q3 2024.

Goldman Sachs reported no remaining BiomX Inc. Units each consisting of one share of common stock and one Warrant entitling the holder to purchase one-half of a share of common stock position as of Q3 2024 after selling out during the quarter.
Goldman Sachs sold 1,039 BiomX Inc. Units each consisting of one share of common stock and one Warrant entitling the holder to purchase one-half of a share of common stock shares in Q3 2024, an estimated $2.91K.
Goldman Sachs first reported a position in BiomX Inc. Units each consisting of one share of common stock and one Warrant entitling the holder to purchase one-half of a share of common stock in Q3 2022 and held it in 8 quarters.
Goldman Sachs's BiomX Inc. Units each consisting of one share of common stock and one Warrant entitling the holder to purchase one-half of a share of common stock position peaked at $7K in Q3 2022.
2 funds tracked by Wall St. Rank held BiomX Inc. Units each consisting of one share of common stock and one Warrant entitling the holder to purchase one-half of a share of common stock as of Q3 2024.

Based on Goldman Sachs's 13F filing for Q3 2024, filed 14 Nov 2024.